|本期目录/Table of Contents|

[1]李健飞,沈闲茹,袁丹.预防性应用他汀药物对脑梗死患者预后的影响[J].慢性病学杂志,2019,20(06):841-843.
点击复制

预防性应用他汀药物对脑梗死患者预后的影响(PDF)

《慢性病学杂志》[ISSN:1674-8166/CN:11-5900/R]

卷:
20
期数:
2019年06期
页码:
841-843
栏目:
专题报道
出版日期:
2019-06-28

文章信息/Info

Title:
-
作者:
李健飞; 沈闲茹; 袁丹
广东省汕头市中心医院，广东 汕头 515031
Author(s):
-
关键词:
脑梗死; 他汀药物; 预后; 危险因素
Keywords:
-
分类号:
R743.3
DOI:
-
摘要:
目的 探讨预防性应用他汀类药物对急性脑梗死患者预后的影响。方法 选取汕头市中心医院2016年 6月至2017年6月起病半年前服用阿托伐他汀（10mg/d）的50例脑梗死患者作为观察组，将同期入院前未应用 他汀类的50例脑梗死患者作为对照组，比较两组患者血管病危险因素、脑梗死严重程度，入院给予相同治疗方案 治疗2周后检查预后良好比例、血脂水平。结果 两组入院时血管病危险因素、脑梗死严重程度比较，差异无统 计学意义（P>0.05）；治疗后，观察组较对照组甘油三酯（TG）、总胆固醇（TC）、低密度脂蛋白胆固醇 （LDL-C）、高密度脂蛋白胆固醇（HDL-C）及Barthel指数评分情况改善明显，差异有统计学意义（P<0.05）。 结论 预防性应用他汀类药物治疗能够显著改善脑梗死后14d的生活能力，减少致残程度。
Abstract:
-

参考文献/References:


[1] Adams HP, Bendixen BH, Kappelle LJ,et al. Classifica-tion of subtype of acute ischemic stroke [J]. Stroke, 1993, 24(1):35-41.
[2] Vaughan CJ, Gotto Jr AM. Basson CT. The evolving role of statins in the management of atherosclerosis [J]. J Am Coll Cardiol,2000,35(1):1-10.
[3] Amin-Hanjani S, Stagliano NE, Yamada M,et al. Mev-astatin, an HMG-CoA reductase inhibitor, reduces stroke damage and upregulates endothelial nitric oxide synthase in mice [J]. Stroke,2001,32(4):980-986.
[4] Rosenson RS. Biological basis for statin therapy in stroke prevention [J]. Curr Opin Neurol,2000,13(1):57-62.
[5] Vaughan CJ, Delanty N. Neuroprotective properties of statins in cerebral ischemia and stroke [J]. Stroke, 1999,30 (9):1969-1973.
[6] Salonen R, Nyyss?nen K, Porkkala E, et al. A popula-tion- based primary preventive trial of the effect of LDL lowering on atherosclerotic progression in carotid and femo-ral arteries [J]. Circulat, 1995,92(7):1758-1764.
[7] Wolfe CD, Taub NA, Woodrow EJ,et al. Assessment of scales of disability and handicap for stroke patients [J]. Stroke,1991,22(10):1242-1244.
[8] Amarenco P. Hypercholesterolemia, lipid-lowering agents, and the risk for brain infarction [J]. Neurol, 2001,57(5): S35-S44.
[9] Joan MF, Meritxell G, Arboix A, et al. Favorable Out-come of Ischemic Stroke in Patients Pretreated with Statins [J]. Stroke,2004,35(5):1117-1121.
[10] Jonsson N, Asplund K. Does pretreatment with statins im-prove clinical outcome after stroke? A pilot case-referent study [J]. Stroke, 2001,32(5):1112-1115.
[11] Goldstein LB, Amarenco P, Zivin J,et al. Statin treat-ment and stroke outcome in the stroke prevention by ag-gressive reduction in cholesterol levels (SPARCL) trial [J]. Stroke,2009,40(11):3526-3531.
[12] Nicholas JS, Swearingen CJ, Thomas JC,et al. The ef-fect of statin pretreatment on infarct volume in ischemic stroke [J]. Neuroepidemiol, 2008,31(1):48-56.
[13] Hess DC, Demchuk AM, Brass LM,et al. HMG-CoA reductase inhibitors (statins). A promising approach to stroke prevention [J]. Neurol, 2000,54(4):790-796.
[14] Byington RP, Davis BR, Plehn JF,et al. Reduction of stroke events with pravastatin. The prospective pravastatin pooling (PPP) project [J]. Circulat,2001,103(3):387-392.
[15] Dyker AG, Weir CJ, Lees KR. Influence of cholesterol on survival after stroke: retrospective study [J]. BMJ,1997, 314(7094):1584-1588.
[16] Gewaltig MT, Kojda G. Vasoprotection by nitric oxide: mechanisms and therapeutic potential [J]. Cardiovasc Res, 2002,55(2):250-260.
[17] Nadareishvili Z, Hallenbeck J. Neuronal regeneration after stroke [J]. N Engl J Med, 2003,348(23):2355-2356.
[18] Rosenson RS. Biological basis for statin therapy in stroke prevention [J]. Curr Opin Neurol,2000,13(1):57-62.
[19] Endres M, Laufs U, Huang Z,et al. Stroke prevention by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhib-itors mediated by endothelial nitric oxide synthase [J]. Proc Natl Acad Sci USA,1998,95(15):8880-8885.
[20] Berger C, Xia F, Maurer MH,et al. Neuroprotection by pravastatin in acute ischemic stroke in rats [J]. Brain Res Rev,2008,58(1):48-56.

备注/Memo

备注/Memo:
基金项目：汕头市医疗科技计划项目（汕府科【2015】123号） 作者简介：李健飞，大学本科，主治医师，研究方向：老 年病学科 通信作者：李健飞，E-mail:24941387@qq.com
更新日期/Last Update: 2019-06-28